{"created":"2023-05-15T15:02:28.332710+00:00","id":84707,"links":{},"metadata":{"_buckets":{"deposit":"d31e4949-caa4-4791-9e9a-e01d5bf08b56"},"_deposit":{"created_by":1,"id":"84707","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"84707"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00084707","sets":["1"]},"author_link":["1022186","1022185","1022188","1022182","1022184","1022187","1022181","1022183","1022189"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"21","bibliographicPageStart":"5380","bibliographicVolumeNumber":"13","bibliographic_titles":[{"bibliographic_title":"Cancers"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear.\nAim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I.\nMethod: The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors?\nResults: A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events.\nConclusions: despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear.","subitem_description_type":"Abstract"}]},"item_8_relation_13":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"34771545","subitem_relation_type_select":"PMID"}}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.3390/cancers13215380","subitem_relation_type_select":"DOI"}}]},"item_8_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.mdpi.com/2072-6694/13/21/5380","subitem_relation_type_select":"URI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2072-6694","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Barcellini, Amelia"}],"nameIdentifiers":[{"nameIdentifier":"1022181","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Loap, Pierre"}],"nameIdentifiers":[{"nameIdentifier":"1022182","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Murata, Kazutoshi"}],"nameIdentifiers":[{"nameIdentifier":"1022183","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Villa, Riccardo"}],"nameIdentifiers":[{"nameIdentifier":"1022184","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kirova, Youlia"}],"nameIdentifiers":[{"nameIdentifier":"1022185","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okonogi, Noriyuki"}],"nameIdentifiers":[{"nameIdentifier":"1022186","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Orlandi, Ester"}],"nameIdentifiers":[{"nameIdentifier":"1022187","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kazutoshi, Murata","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1022188","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Noriyuki, Okonogi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1022189","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-11-15"},"publish_date":"2021-11-15","publish_status":"0","recid":"84707","relation_version_is_last":true,"title":["PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T18:15:05.943848+00:00"}